Scholarlink

<p>This study investigated the role of mitochondrial function in aortic aging. As the aorta ages, it becomes stiffer and less compliant, increasing the risk of aneurysmal disease, hypertension, and diastolic dysfunction. Given the role of mitochondrial dysfunction in non-age related aortopathies and as a hallmark of aging, we investigated its contribution to the aging aorta. Both male and female young (5–6&#xa0;month) and aged (24–25&#xa0;month) C57Bl/6&#xa0;J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8&#xa0;weeks. ELAM restored complex II-linked respiration in aged mice to values seen in young mice, while also improving relative phosphorylative flux. ELAM treatment also reduced inflammatory MMP9 expression and elastin breaks in aged mice. Bulk RNAseq analysis revealed that ELAM treatment significantly affected the aortic transcriptome in an age-dependent manner, reducing the expression of senescent and associated pro-inflammatory genes. Mitochondrial dysfunction thus drives aortic aging and is a potential therapeutic target for future study.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta

  • 期刊论文

  • 发表日期：

    2025年11月13日

查看全文
  • Arjune S. Dhanekula,
  • Benjamin R. Harrison,
  • Gavin Pharaoh,
  • Aurora Mattson-Hughes,
  • Stefano Tarantini,
  • Rudolph Stuppard,
  • Scott C. DeRoo,
  • Christopher R. Burke,
  • Billiana Hwang,
  • Jay D. Pal,
  • Michael S. Mulligan,
  • David J. Marcinek

摘要

This study investigated the role of mitochondrial function in aortic aging. As the aorta ages, it becomes stiffer and less compliant, increasing the risk of aneurysmal disease, hypertension, and diastolic dysfunction. Given the role of mitochondrial dysfunction in non-age related aortopathies and as a hallmark of aging, we investigated its contribution to the aging aorta. Both male and female young (5–6 month) and aged (24–25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks. ELAM restored complex II-linked respiration in aged mice to values seen in young mice, while also improving relative phosphorylative flux. ELAM treatment also reduced inflammatory MMP9 expression and elastin breaks in aged mice. Bulk RNAseq analysis revealed that ELAM treatment significantly affected the aortic transcriptome in an age-dependent manner, reducing the expression of senescent and associated pro-inflammatory genes. Mitochondrial dysfunction thus drives aortic aging and is a potential therapeutic target for future study.

Graphical Abstract